Inhaled ciclesonide is well-tolerated in children with persistent asthma: results from the rainbow study Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
High or standard initial dose of budesonide to control mild-to-moderate asthma? Source: Eur Respir J 2001; 17: 856-862 Year: 2001
Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003
Once-daily inhaled corticosteroids in children with asthma: Not a simple solution for non-adherence Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013
QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: The ARISE study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
Comparitive study for evaluation of efficacy and safety of doxofylline and theophylline in chronic persistent asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009
A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
The patient’s role in the choice of new inhaler devices and dosing regimens for asthma and COPD: A preference study Source: International Congress 2016 – Kaleidoscope of respiratory nursing Year: 2016
Budesonide/formoterol adjustable maintenance dosing effectively improves asthma symptom severity: a multicentre Canadian study Source: Eur Respir J 2003; 22: Suppl. 45, 258s Year: 2003
Efficacy of inhaled heparin is effective in the treatment of acute exacerbation of asthma Source: Annual Congress 2007 - New drugs for asthma Year: 2007
Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
Single-dose indacaterol, a novel 24-hour β2 -agonist, is well tolerated in patients with mild asthma Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005
Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial Source: Eur Respir J 2007; 30: 457-466 Year: 2007
Short-acting bronchodilator reversibility does not predict the response to long-term treatment by indacaterol 150 µg in COPD: REVERBREZ study Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation Year: 2013
Safety of once-daily glycopyrronium in patients with severe-to-very severe COPD: The SPARK study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013
The development of an algorithm for the rational use of intravenous salbutamol in severe paediatric asthma Source: Annual Congress 2008 - Treatment and outcome of childhood asthma: new perspectives Year: 2008
Ciclesonide is effective in the treatment of bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 95s Year: 2001
Efficacy of montelukast in Indian patients having chronic persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 372s Year: 2003
Indacaterol, a novel once-daily β2 -agonist, is well tolerated in persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 204s Year: 2006